Anupam Rasayan India Ltd

- No new long-term debt fundraising is planned; management expects long-term debt to be practically zero by FY '27, largely through warrant conversions in FY '26. - Proceeds from warrant conversion in FY '26 will be used to repay approximately INR185 crores of long-term debt, aiding deleveraging. - Short-term debt (~INR1,100 crores) will be used primarily as a balancing figure for working capital utilization; no significant repayment pressure expected. - No immediate equity fundraising is mentioned; focus appears to be on utilizing existing resources and warrant proceeds. - Capex needs for new projects (e.g., Elementium product) will be evaluated and communicated later; initial ramp-ups are planned within current capacities without extra capex.

- No additional capex required for servicing the first 1,000 tons of demand for the new AI product; this will be met with current capacities. - Potential capex will be considered only upon ramp-up or securing a take-or-pay contract for higher volumes. - Current assets can support production worth INR60-70 crores annually for Elementium orders; possible debottlenecking can increase this to INR100 crores without major capex. - For scaling Elementium's full potential (approx. $70-$90 million revenue p.a.), significant capex will be necessary. - INR670 crores of planned capex completed, with two manufacturing facilities commercialized and one facility ready for commercialization imminently. - Capex will focus on expanding production capacity to support next-phase growth and new molecule launches. - No term debt expected by FY '27, as warrant conversions will largely repay it; short-term debt primarily balances working capital needs. - Management will share detailed capex plans in future calls once finalized.

- Company targets a return to historical revenue growth rates of 25%-30%+ from FY '26 onwards. - Majority of LOIs worth approx. INR14,600 crores will commercialize over 4-10 years, contributing ~INR2,000 crores annual incremental revenue over 2-3 years. - New product ramp-ups, especially in Pharma (20%-25% of revenue in FY '26) and Polymer/Performance Chemicals (expected to rise to 25%+ revenue in FY '26), plus recovery in agrochemicals expected to drive volume growth. - Agrochemical demand is rebounding with volume-led growth; new high-value AI molecules contribute significantly with triple-digit dollar per kg pricing. - Volume, rather than price, is expected to drive growth; pricing impact is minimal. - LOI commercialization progressing: ~INR200 crores revenue already from 2022 LOIs; 2023 LOIs expected to commercialize by 2026. - Current capacities support initial volumes; significant capex planned to meet higher-scale production needs by FY '27 and beyond.

- Company targets a return to historical growth rates of 25-30%+ from FY '26 onwards. - Revenue growth driven by commercialization and ramp-up of LOIs, expected to mature over 2-4 years. - Pharma and Polymer segments are key growth drivers, with Pharma expected to be 20-25% and Polymer 25%+ of revenue in FY '26. - EBITDA margins are expected to remain consistent in the 26-28% range, supported by diversified product mix. - Operating cash flow generation is strong (INR 140+ crores in the recent half), with expectations for improvement via working capital optimization. - Long-term debt is planned to be reduced to near zero by FY '27 through warrant conversions. - Working capital days target is around 150-180 days for incremental revenues, supporting cash flow efficiency. - New high-value molecules, including AI and EV battery chemicals, offer significant revenue upside with triple-digit dollar/kg pricing.

- Current order book stands at approximately INR 14,646 crores, spread over 4 to 10 years. - Out of this, INR 3,100 crores worth of LOIs and contracts have already been commercialized. - These commercialized orders contribute to over 20% of revenue in FY '25. - Majority of the remaining LOIs and contracts are expected to be commercialized in FY '26. - A significant LOI product in the agrochemical segment (an AI molecule) was signed in Q4 2022 and is currently ramping up, expected to contribute triple-digit million dollar revenue. - The orderbook supports expected revenue ramp-ups, including around $70-90 million from key products. - Strong order book, new product launches, and enhanced capacity underpin confidence in returning to historical growth rates.